Table 5.

Independent risk factors for MACE and death in the study population (multivariate analysis, A1A1 (n = 690), A1A2 (n = 248), A2A2 (n = 25))

	MACE *			Death **
	RR	95% CI	p	RR	95% CI	p
LVEF < 40%	2.07	1.37–3.13	0.001	2.81	1.53–5.16	0.001
Follow-up
Beta-blocker no/yes	2.46	1.70–3.56	< 0.001	10.64	4.54–24.94	< 0.001
ACE inhibitor no/yes	2.63	1.65–4.18	< 0.001	8.91	2.74–28.98	< 0.001

* For MACE, Cox multivariable model included: hypercholesterolemia, coronary artery disease extent, LVEF, treatments during follow-up (statin and/or betablocker and/or ACE inhibitor), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model.

** For death, Cox multivariable model included: age, hypercholesterolemia, past or current smoking, prior MI, family history of MI, coronary artery disease extent, LVEF, revascularisations during follow-up (PCI, CABG), treatment during follow-up (ACE inhibitor, betablocker, statin), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model.

ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CI, confidence interval; LVEF, left ventricular ejection fraction; MACE, major adverse coronary event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk.